ArticleEuropean journal of medical research2025
Illuminating the intricate role of genetic factors in chronic low back pain: from the molecular basis of onset to the determination of susceptibility and the search for novel therapeutic avenues.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundInterleukin 6 receptor (IL6R) inhibitors are effective drugs as therapy for rheumatoid arthritis (RA). However, few studies on IL6R inhibition for relieving chronic low back pain (CLBP) have been conducted. These existing studies are plagued by issues such as small sample sizes and inconsistent inclusion criteria. With advances in genomics, more and more evidence is revealing the role of heritability in the etiology of disease, and Mendelian randomization (MR) analyses are being used more broadly to infer causation. MR analysis was used in the present study to investigate the effect of IL6R inhibitors on CLBP.
methodsIL6R single nucleotide polymorphisms (SNPs) from Europe were selected from online databases. C-reactive protein (CRP) levels were utilized as an exposure factor, RA was employed as a positive control, and two CLBP-related genome-wide association studies (GAWS) data were used as primary outcomes for drug-targeted MR analyses for examining causality between IL6R inhibitors and CLBP. In addition, repeated analyses were also performed using different GWAS data related to exposure to test the stability of the results.
resultsIL6R inhibitors significantly reduced the risk of CLBP, ukb-a-346 (OR: 0.9564, 95% CI 0.9353-0.9774, P = 3.35 × 10
conclusionThe results of this MR study indicate that IL6R may contribute to the pathogenesis of CLBP and that inhibition of IL6R reduces the risk of CLBP. These findings may guide future studies and offer more favorable drug choices for individuals at risk of CLBP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.